查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1995505

驅蟲藥市場：2026-2032年全球市場預測（依藥物類別、目標動物、給藥途徑、劑型及銷售管道）

Anthelmintic Drugs Market by Drug Class, Animal Type, Route Of Administration, Formulation, Sales Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2025 年驅蟲藥市場價值 38.6 億美元，預計到 2026 年將成長至 41.7 億美元，年複合成長率為 8.28%，到 2032 年將達到 67.4 億美元。

主要市場統計數據
基準年 2025 38.6億美元
預計年份：2026年 41.7億美元
預測年份 2032 67.4億美元
複合年成長率 (%) 8.28%

全面概述了驅蟲藥在人類和動物健康治療中的重要性、臨床挑戰和商業性需求。

驅蟲藥仍然是獸醫學和人類寄生蟲病防治的基石，在動物健康、公共衛生和農業生產力方面都帶來了顯著的益處。此治療領域涵蓋多種化學類型和給藥方法，主要針對線蟲、絛蟲和吸蟲，其正確應用對於維護動物福利和食品安全至關重要。臨床醫生、生產者和公共衛生部門日益面臨著許多複雜的挑戰，包括寄生蟲抗藥性的不斷演變、監管要求的不斷變化，以及在最大限度減少環境和殘留問題的同時最佳化治療效果的壓力。

演化壓力、科學創新和監管趨同正在重塑驅蟲治療領域的商業策略和合理使用模式。

驅蟲藥領域正經歷著一場變革，其驅動力包括分子層面的創新、日益嚴重的抗藥性以及監管和永續性挑戰的交匯。新型化學結構和製劑技術的出現正在拓展治療手段，延長藥效持續時間，改善偏好，並提供更符合終端用戶需求的替代給藥途徑。同時，基因組監測和現場診斷揭示了異質性抗藥性的出現，因此亟需制定有針對性的管理方案和區域性治療流程。

2025 年推出的貿易政策調整將對永續供應鏈和採購造成挑戰，這將影響製造業決策和商業性定價趨勢。

美國將於2025年實施一系列關稅調整，其累積影響正促使整個驅蟲藥價值鏈在供應鏈最佳化、籌資策略和定價模式等方面面臨新的考量。進口關稅及相關貿易措施提高了從國際製造地採購的某些活性藥物成分和成品的接收成本，促使採購團隊重新評估供應商多樣性，並加快對替代生產商的認證。同時，分銷合作夥伴和獸藥批發商正在審查庫存管理和避險策略，以緩解利潤率壓力，並維持關鍵治療產品的供應連續性。

對藥理分類、目標動物群體、給藥途徑、製劑類型和銷售管道趨勢的詳細細分分析揭示了具體的商業化機會。

細分市場層面的趨勢揭示了每種藥物類別、目標動物群體、給藥途徑、製劑類型和銷售管道各自獨特的臨床和商業性發展軌跡，因此需要製定針對性的策略來應對這些差異。從藥物類別來看，該領域的主要特徵包括：傳統的苯並咪唑酮，它們在許多治療通訊協定中仍然發揮著關鍵作用；咪唑並噻唑類和四氫嘧啶類藥物，它們針對特定寄生蟲群體提供互補的動態特徵；以及大環內酯類藥物，它們因其頻譜活性和長效製劑而備受重視。每類藥物都有其固有的抗藥性風險，因此需要製定藥物管理計劃，使給藥方案與診斷數據相符。

美洲、歐洲、中東和非洲以及亞太地區的區域流行病學差異、監管多樣性和分銷成熟度，為市場進入和產品引進創造了不同的途徑。

由於流行病學、監管要求和分銷基礎設施的差異，驅蟲治療的區域趨勢各不相同，這導致生產商和供應商的優先事項也各不相同。美洲地區除了擁有成熟的分銷網路、廣泛的獸醫網路以及優先考慮生產力和遵守殘留限量的大規模畜牧生產系統外，對伴侶動物護理創新方面的需求也日益成長。在該地區，綜合服務模式和以診斷主導的治療通訊協定正逐漸得到推廣，以最佳化治療效果並解決抗藥性問題。

競爭格局是由合作模式塑造的，這種模式整合了傳統的製藥優勢、專業創新以及診斷、製造和分銷管道的柔軟性。

驅蟲藥領域主要企業之間的競爭格局體現了傳統製藥能力、針對性創新投資和策略夥伴關係的融合。成熟的動物用藥品公司繼續利用其豐富的臨床試驗經驗、監管專業知識和強大的分銷網路，以維持其在畜牧業和伴侶動物領域的市場地位。同時，專業的生物技術公司和規模較小的創新者正在開發整合新型分子、製劑改進和診斷功能的產品組合，旨在解決抗藥性熱點問題並創造差異化的價值提案。

為製藥企業和經銷商制定可操作的優先事項，以將治療方法創新、管理計劃和供應彈性與通路特定的商業化策略相結合。

產業領導企業應採取多層次策略，將產品創新與產品管理、供應鏈韌性和以通路為中心的商業化結合。優先發展具備診斷能力的治療模式，既能延長治療藥物的生命週期，又能創造提供優質服務的機會。將診斷數據整合到商業性價值提案中，有助於在競爭激烈的治療領域中實現產品差異化。同時，投資於劑型多樣化，例如為伴侶動物開發偏好極佳的口服懸浮液，以及為牲畜開發緩釋注射劑，可以提高用藥依從性，並滿足多樣化的臨床需求。

結合文獻整合、專家訪談和情境映射的穩健混合方法，確保透明且可操作的市場洞察。

這些洞見所依據的研究和分析採用了混合方法，結合了系統性文獻綜述、質性訪談和結構化相關人員對話。文獻綜述查閱了同行評審的臨床研究、監管指導文件和技術報告，以掌握最新的科學和安全考量。一手資訊則透過與獸醫、藥物監測專家、醫院採購經理、契約製造製造商和行業顧問的保密訪談收集，以確定實際應用中的營運挑戰和促進因素。

將管理、創新和供應鏈適應性作為驅蟲治療永續成功的基礎，以應對策略挑戰。

總之，驅蟲藥領域正處於一個十字路口，臨床需求與商業性和監管的複雜性相互交織。新出現的抗藥性、新的製劑機會以及不斷變化的貿易趨勢，都要求我們制定一項具有前瞻性的策略，優先考慮診斷整合、藥物管理和供應鏈多元化。應對流行病學和管理體制的區域差異，需要採取市場最佳化的方法，既要體現當地的優先事項，又要保持產品定位和循證醫學證據生成的全球一致性。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：驅蟲藥市場：依藥物類別分類

  • 苯並咪唑酮
  • 咪唑並噻唑和四氫嘧啶
  • 大環內酯

第9章：驅蟲藥市場：依動物類型分類

  • 伴侶動物
    • 貓
    • 狗
  • 肉類動物
    • 牛
    • 家禽
    • 綿羊和山羊
    • 豬
  • 人類
    • 成人
    • 兒童

第10章：驅蟲藥市場：依給藥途徑分類

  • 口服
  • 腸外
  • 外用

第11章：以劑型分類的驅蟲藥市場

  • 注射藥物
  • 口服懸浮液
  • 藥片

第12章：驅蟲藥市場：依銷售管道分類

  • 網路藥房
  • 零售藥房
  • 動物用藥品批發商
  • 獸醫醫院和診所

第13章：驅蟲藥市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章：驅蟲藥市場：依類別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章：驅蟲藥市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國驅蟲藥市場

第17章：中國抗寄生蟲藥物市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Aden Healthcare
  • Anikem Laboratories
  • Bayer AG
  • Boehringer Ingelheim International GmbH
  • Ceva Sante Animale
  • Cipla Limited
  • Dechra Pharmaceuticals PLC
  • Dr.Reddys Laboratories Inc.
  • Edenbridge Pharmaceuticals LLC
  • GlaxoSmithKline PLC
  • Green Cross Remedies
  • Healthy Life Pharma Private Limited
  • Johnson & Johnson Services, Inc.
  • Kosher Pharmaceuticals
  • Lineage Therapeutics Inc
  • Lupin Limited
  • Mankind Pharma Ltd.
  • McKesson Corporation
  • Merck & Co., Inc.
  • Norbrook Laboratories Limited
  • Novartis AG
  • Sankur Pharmaceuticals Pvt. Ltd
  • Takeda Pharmaceutical Company Limited
  • Virbac SA
  • Weefsel Pharma
Product Code: MRR-FB6C9E792F81

The Anthelmintic Drugs Market was valued at USD 3.86 billion in 2025 and is projected to grow to USD 4.17 billion in 2026, with a CAGR of 8.28%, reaching USD 6.74 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 3.86 billion
Estimated Year [2026] USD 4.17 billion
Forecast Year [2032] USD 6.74 billion
CAGR (%) 8.28%

Comprehensive orientation to anthelmintic therapeutic importance, clinical pressures, and commercial imperatives shaping treatment approaches across human and animal health

Anthelmintic drugs remain a cornerstone of veterinary and human parasitic disease management, delivering measurable benefits across animal health, public health, and agricultural productivity. The therapeutic category encompasses a range of chemotypes and administration approaches that target nematodes, cestodes, and trematodes, and their appropriate deployment is critical to sustaining animal welfare and food safety. Clinicians, producers, and public health authorities increasingly face a complex interplay of evolving parasite resistance, shifting regulatory expectations, and pressure to optimize therapeutic efficacy while minimizing environmental and residue concerns.

Against this backdrop, stakeholders require concise, evidence-driven analysis that frames clinical and commercial priorities. This report synthesizes current scientific developments, regulatory trends, and distribution channel dynamics to enable decision-makers to align research and development pipelines, procurement strategies, and market access initiatives. By integrating clinical context with operational realities, this introduction sets the stage for deeper examination of market-moving forces and tactical options available to manufacturers, distributors, and policy makers.

Evolutionary pressures, scientific innovations, and regulatory convergence are reshaping commercial strategies and stewardship models across anthelmintic therapeutics

The landscape for anthelmintic drugs is undergoing transformative shifts driven by innovation in molecular classes, rising resistance patterns, and the convergence of regulatory and sustainability agendas. Novel chemistries and formulation technologies are expanding the therapeutic toolkit, enabling longer duration of action, improved palatability, and alternative delivery modalities that better match end-user needs. Concurrently, genomic surveillance and field-level diagnostics are revealing heterogeneous resistance emergence that requires targeted stewardship programs and region-specific treatment algorithms.

Commercial models are adapting as well, with manufacturers investing in value-added services such as diagnostic-driven treatment recommendations and bundled supply solutions for large livestock operations. Regulatory frameworks are increasingly emphasizing residue monitoring, environmental risk assessment, and rigorous product lifecycle data, prompting earlier and more integrated regulatory strategy workstreams. These shifts underscore the need for market participants to pivot from product-centric plans to integrated service offerings that combine therapeutic efficacy with demonstrable stewardship and sustainability credentials. As a result, partnerships between pharmaceutical developers, diagnostic firms, and distribution networks are becoming a central feature of competitive positioning in this sector.

Trade policy adjustments introduced in 2025 have created sustained supply chain and sourcing imperatives that influence manufacturing decisions and commercial pricing dynamics

The cumulative impact of tariff changes initiated in the United States during 2025 has introduced new considerations for supply chain optimization, sourcing strategy, and pricing models across the anthelmintic drugs value chain. Import duties and related trade measures have increased landed costs for certain active pharmaceutical ingredients and finished formulations sourced from international manufacturing hubs, prompting procurement teams to reassess supplier diversity and to accelerate qualification of alternative manufacturers. In parallel, distribution partners and veterinary wholesalers have revisited inventory and hedging practices to mitigate margin pressure and to preserve continuity of supply for critical therapeutic lines.

These developments have also incentivized a deliberate reconsideration of regional manufacturing investments and nearshoring strategies to reduce exposure to tariff volatility and to enhance responsiveness to local regulatory approvals. Firms with greater vertical integration or flexible contract manufacturing capabilities have found opportunities to stabilize pricing and delivery, while smaller companies face heightened negotiation complexity with channel partners. In response, commercial teams are refining contractual terms, exploring tariff classification optimizations, and deepening collaboration with customs and trade advisors to navigate compliance while preserving customer access to essential products.

Granular segment insights across pharmacological classes, animal cohorts, administration routes, formulation types, and channel behaviors reveal targeted opportunities for commercialization

Segment-level dynamics reveal differentiated clinical and commercial trajectories that require targeted strategies across drug classes, animal cohorts, administration routes, formulation types, and sales channels. Based on drug class, the field is characterized by traditional benzimidazoles which continue to serve as backbone agents in many protocols, imidazothiazoles and tetrahydropyrimidines that offer complementary pharmacodynamic profiles for specific parasite groups, and macrocyclic lactones which are prized for broad-spectrum activity and long-acting formulations. Each class presents distinct resistance risks and requires stewardship planning that aligns dosing regimens with diagnostic data.

Based on animal type, the commercial and clinical landscapes diverge meaningfully. Companion animals prioritize safety, taste, and convenient administration, with companion animal cohorts further differentiated into cats and dogs that have unique tolerability and product preference patterns. Food producing animals focus on production economics and residue compliance, with cattle, poultry, sheep and goat, and swine exhibiting varied parasite exposure and management frameworks that drive treatment frequency and product choice. The human segment requires rigorous safety and regulatory oversight with adult and pediatric subpopulations demanding tailored dosing and formulation considerations. Based on route of administration, product selection and adoption hinge on oral therapies favored for ease of use, parenteral options chosen for bioavailability and controlled delivery, and topical preparations selected for localized application and owner convenience.

Based on formulation, injectable preparations deliver reliable plasma concentrations for systemic infections, oral suspensions meet needs for flexible dosing across weight ranges, and tablets remain a staple where stability and dosing accuracy are paramount. Based on sales channel, adoption and access are shaped by online pharmacies that expand reach and convenience, retail pharmacies that serve human and companion animal markets, veterinary distributors that bridge manufacturers and clinical end users, and veterinary hospitals and clinics that serve as primary points of care and influence repeat purchase behavior. Understanding these intersecting segment dynamics enables more precise product positioning, pricing strategies, and lifecycle management decisions that reflect both clinical performance and customer preferences.

Regional epidemiology, regulatory diversity, and distribution maturity across the Americas, EMEA, and Asia-Pacific create distinct pathways for market access and product adoption

Regional dynamics in anthelmintic therapeutics vary by epidemiology, regulatory requirements, and distribution infrastructure, shaping differentiated priorities for manufacturers and suppliers. The Americas region exhibits mature distribution frameworks, widespread veterinary practice networks, and increasing demand for innovation in companion animal care alongside large-scale livestock production systems that prioritize productivity and residue compliance. In this region, integrated service models and diagnostic-driven treatment protocols are gaining traction to optimize therapeutic outcomes and to address resistance concerns.

Europe, Middle East & Africa present a complex mosaic of market conditions where stringent regulatory oversight in parts of Europe coexists with variable access and infrastructure constraints across other countries. This diversity requires adaptable market access strategies that balance regulatory rigor, affordability, and targeted education initiatives to support appropriate use. In several countries within this geography, environmental considerations and sustainability reporting are becoming prominent purchase criteria, influencing formulation development and post-market monitoring.

Asia-Pacific encompasses high-growth livestock sectors, an expanding companion animal market, and diverse regulatory regimes that range from highly structured to evolving frameworks. Rapid adoption of digital distribution channels and a growing appetite for value-added services are notable across the region. Manufacturers operating here must navigate heterogeneous reimbursement and procurement landscapes while leveraging regional manufacturing capacity to enhance supply resilience and to meet local demand patterns.

Competitive landscape shaped by legacy pharmaceutical strengths, specialized innovation, and collaborative models that integrate diagnostics, manufacturing flexibility, and channel influence

Competitive dynamics among leading organizations in the anthelmintic space reflect a mix of legacy pharmaceutical capabilities, targeted innovation investments, and strategic partnerships. Established animal health pharmaceutical firms continue to leverage extensive clinical trial experience, regulatory know-how, and deep distribution networks to sustain presence in both livestock and companion animal segments. At the same time, specialist biotech and smaller innovators are advancing novel molecules, reformulations, and diagnostic-integrated offerings that aim to address resistance hotspots and to create differentiated value propositions.

Partnerships between diagnostics providers and therapeutic developers are emerging as a critical vector for competitive advantage, as real-world diagnostic data enables more precise treatment algorithms and supports stewardship narratives. Contract manufacturing organizations with flexible capacity and quality systems are increasingly strategic allies for companies seeking to scale production or to diversify geographic sourcing. Additionally, distributors and veterinary service networks that invest in training and digital engagement are gaining influence over prescribing patterns and can accelerate uptake of new products through bundled service models and clinician education initiatives.

Actionable priorities for manufacturers and distributors to align therapeutic innovation, stewardship programs, and supply resilience with channel-specific commercialization tactics

Industry leaders should pursue a multilayered approach that aligns product innovation with stewardship, supply resilience, and channel-centric commercialization. Prioritizing diagnostic-enabled treatment paradigms will both extend therapeutic lifespans and create opportunities for premium service offerings; integrating diagnostic data into commercial value propositions can distinguish products in crowded therapeutic classes. Concurrently, investing in formulation versatility-such as palatable oral suspensions for companion animals and extended-release injectables for livestock-will improve adherence and meet diverse clinical needs.

From a supply perspective, diversifying sourcing through regional manufacturing partnerships and qualified contract manufacturers can reduce exposure to tariff and logistics volatility while shortening lead times. Commercially, companies should develop tailored go-to-market strategies for different channels, including omnichannel approaches for retail and online pharmacies, and service bundles for veterinary hospitals and distributors that incentivize stewardship-aligned prescribing. Finally, embedding environmental risk assessments and residue management into product lifecycle planning will address regulator and customer expectations, supporting long-term market acceptance and license-to-operate objectives.

Robust mixed-methods approach combining literature synthesis, primary expert interviews, and scenario mapping to ensure transparent and actionable market insights

The research synthesis underpinning these insights draws on a mixed-methods approach that combines systematic literature review, primary qualitative interviews, and structured stakeholder engagement. The literature review surveyed peer-reviewed clinical studies, regulatory guidance documents, and technical reports to capture contemporary scientific and safety considerations. Primary inputs were gathered through confidential interviews with veterinarians, pharmacovigilance experts, hospital procurement leads, contract manufacturers, and trade advisors to surface operational challenges and real-world adoption drivers.

Analytical techniques included cross-sectional thematic analysis of qualitative data to identify recurring market signals, triangulation of regulatory trends to assess evolving compliance expectations, and scenario mapping to evaluate the implications of trade policy shifts and resistance emergence. Data quality was maintained through source triangulation and expert validation rounds. The methodology emphasizes transparency in assumptions and traceability of insights, enabling readers to understand the evidence base and to adapt findings to their organization's strategic context.

Synthesis of strategic imperatives highlighting stewardship, innovation, and supply chain adaptability as the foundation for sustainable success in anthelmintic therapeutics

In conclusion, the anthelmintic drugs domain is at an inflection point where clinical necessity intersects with commercial and regulatory complexity. The interplay of emerging resistance, novel formulation opportunities, and changing trade dynamics necessitates proactive strategies that prioritize diagnostic integration, stewardship, and supply chain diversification. Regional variation in epidemiology and regulatory regimes requires bespoke market approaches that reflect local priorities while preserving global coherence in product positioning and evidence generation.

Organizations that harmonize scientific rigor with flexible commercial models will be best positioned to deliver both clinical value and sustainable growth. By focusing on targeted innovation, strengthened distribution partnerships, and data-driven stewardship, stakeholders can navigate near-term disruptions and build resilient pathways for long-term therapeutic relevance. These conclusions provide a pragmatic blueprint for aligning R&D, regulatory, and commercial activities to meet the evolving needs of clinicians, producers, and public health decision-makers.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Anthelmintic Drugs Market, by Drug Class

  • 8.1. Benzimidazoles
  • 8.2. Imidazothiazoles And Tetrahydropyrimidines
  • 8.3. Macrocyclic Lactones

9. Anthelmintic Drugs Market, by Animal Type

  • 9.1. Companion Animals
    • 9.1.1. Cats
    • 9.1.2. Dogs
  • 9.2. Food Producing Animals
    • 9.2.1. Cattle
    • 9.2.2. Poultry
    • 9.2.3. Sheep And Goat
    • 9.2.4. Swine
  • 9.3. Human
    • 9.3.1. Adults
    • 9.3.2. Pediatric

10. Anthelmintic Drugs Market, by Route Of Administration

  • 10.1. Oral
  • 10.2. Parenteral
  • 10.3. Topical

11. Anthelmintic Drugs Market, by Formulation

  • 11.1. Injectable
  • 11.2. Oral Suspension
  • 11.3. Tablet

12. Anthelmintic Drugs Market, by Sales Channel

  • 12.1. Online Pharmacies
  • 12.2. Retail Pharmacies
  • 12.3. Veterinary Distributors
  • 12.4. Veterinary Hospitals And Clinics

13. Anthelmintic Drugs Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Anthelmintic Drugs Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Anthelmintic Drugs Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Anthelmintic Drugs Market

17. China Anthelmintic Drugs Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Aden Healthcare
  • 18.6. Anikem Laboratories
  • 18.7. Bayer AG
  • 18.8. Boehringer Ingelheim International GmbH
  • 18.9. Ceva Sante Animale
  • 18.10. Cipla Limited
  • 18.11. Dechra Pharmaceuticals PLC
  • 18.12. Dr.Reddys Laboratories Inc.
  • 18.13. Edenbridge Pharmaceuticals LLC
  • 18.14. GlaxoSmithKline PLC
  • 18.15. Green Cross Remedies
  • 18.16. Healthy Life Pharma Private Limited
  • 18.17. Johnson & Johnson Services, Inc.
  • 18.18. Kosher Pharmaceuticals
  • 18.19. Lineage Therapeutics Inc
  • 18.20. Lupin Limited
  • 18.21. Mankind Pharma Ltd.
  • 18.22. McKesson Corporation
  • 18.23. Merck & Co., Inc.
  • 18.24. Norbrook Laboratories Limited
  • 18.25. Novartis AG
  • 18.26. Sankur Pharmaceuticals Pvt. Ltd
  • 18.27. Takeda Pharmaceutical Company Limited
  • 18.28. Virbac S.A.
  • 18.29. Weefsel Pharma

LIST OF FIGURES

  • FIGURE 1. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ANTHELMINTIC DRUGS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ANTHELMINTIC DRUGS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY ANIMAL TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY FORMULATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY SALES CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES ANTHELMINTIC DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA ANTHELMINTIC DRUGS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY BENZIMIDAZOLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY BENZIMIDAZOLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY BENZIMIDAZOLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY IMIDAZOTHIAZOLES AND TETRAHYDROPYRIMIDINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY IMIDAZOTHIAZOLES AND TETRAHYDROPYRIMIDINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY IMIDAZOTHIAZOLES AND TETRAHYDROPYRIMIDINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY MACROCYCLIC LACTONES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY MACROCYCLIC LACTONES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY MACROCYCLIC LACTONES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY COMPANION ANIMALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY COMPANION ANIMALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY COMPANION ANIMALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY CATS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY CATS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY CATS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY DOGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY DOGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY DOGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY FOOD PRODUCING ANIMALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY FOOD PRODUCING ANIMALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY FOOD PRODUCING ANIMALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY FOOD PRODUCING ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY CATTLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY CATTLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY CATTLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY POULTRY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY POULTRY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY POULTRY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY SHEEP AND GOAT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY SHEEP AND GOAT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY SHEEP AND GOAT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY SWINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY SWINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY SWINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY HUMAN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY HUMAN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY HUMAN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY HUMAN, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY ADULTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY ADULTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY ADULTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY PARENTERAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY PARENTERAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY ORAL SUSPENSION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY ORAL SUSPENSION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY ORAL SUSPENSION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY TABLET, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY TABLET, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY TABLET, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY VETERINARY DISTRIBUTORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY VETERINARY DISTRIBUTORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY VETERINARY DISTRIBUTORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY VETERINARY HOSPITALS AND CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY VETERINARY HOSPITALS AND CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY VETERINARY HOSPITALS AND CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. AMERICAS ANTHELMINTIC DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 84. AMERICAS ANTHELMINTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 85. AMERICAS ANTHELMINTIC DRUGS MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 86. AMERICAS ANTHELMINTIC DRUGS MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 87. AMERICAS ANTHELMINTIC DRUGS MARKET SIZE, BY FOOD PRODUCING ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 88. AMERICAS ANTHELMINTIC DRUGS MARKET SIZE, BY HUMAN, 2018-2032 (USD MILLION)
  • TABLE 89. AMERICAS ANTHELMINTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 90. AMERICAS ANTHELMINTIC DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 91. AMERICAS ANTHELMINTIC DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 92. NORTH AMERICA ANTHELMINTIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. NORTH AMERICA ANTHELMINTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 94. NORTH AMERICA ANTHELMINTIC DRUGS MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 95. NORTH AMERICA ANTHELMINTIC DRUGS MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 96. NORTH AMERICA ANTHELMINTIC DRUGS MARKET SIZE, BY FOOD PRODUCING ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 97. NORTH AMERICA ANTHELMINTIC DRUGS MARKET SIZE, BY HUMAN, 2018-2032 (USD MILLION)
  • TABLE 98. NORTH AMERICA ANTHELMINTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 99. NORTH AMERICA ANTHELMINTIC DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 100. NORTH AMERICA ANTHELMINTIC DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 101. LATIN AMERICA ANTHELMINTIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. LATIN AMERICA ANTHELMINTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 103. LATIN AMERICA ANTHELMINTIC DRUGS MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 104. LATIN AMERICA ANTHELMINTIC DRUGS MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 105. LATIN AMERICA ANTHELMINTIC DRUGS MARKET SIZE, BY FOOD PRODUCING ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 106. LATIN AMERICA ANTHELMINTIC DRUGS MARKET SIZE, BY HUMAN, 2018-2032 (USD MILLION)
  • TABLE 107. LATIN AMERICA ANTHELMINTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 108. LATIN AMERICA ANTHELMINTIC DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 109. LATIN AMERICA ANTHELMINTIC DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE, MIDDLE EAST & AFRICA ANTHELMINTIC DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE, MIDDLE EAST & AFRICA ANTHELMINTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE, MIDDLE EAST & AFRICA ANTHELMINTIC DRUGS MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE, MIDDLE EAST & AFRICA ANTHELMINTIC DRUGS MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE, MIDDLE EAST & AFRICA ANTHELMINTIC DRUGS MARKET SIZE, BY FOOD PRODUCING ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE, MIDDLE EAST & AFRICA ANTHELMINTIC DRUGS MARKET SIZE, BY HUMAN, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE, MIDDLE EAST & AFRICA ANTHELMINTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE, MIDDLE EAST & AFRICA ANTHELMINTIC DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE, MIDDLE EAST & AFRICA ANTHELMINTIC DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE ANTHELMINTIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE ANTHELMINTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE ANTHELMINTIC DRUGS MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE ANTHELMINTIC DRUGS MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE ANTHELMINTIC DRUGS MARKET SIZE, BY FOOD PRODUCING ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE ANTHELMINTIC DRUGS MARKET SIZE, BY HUMAN, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE ANTHELMINTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE ANTHELMINTIC DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE ANTHELMINTIC DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 128. MIDDLE EAST ANTHELMINTIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. MIDDLE EAST ANTHELMINTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 130. MIDDLE EAST ANTHELMINTIC DRUGS MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. MIDDLE EAST ANTHELMINTIC DRUGS MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 132. MIDDLE EAST ANTHELMINTIC DRUGS MARKET SIZE, BY FOOD PRODUCING ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 133. MIDDLE EAST ANTHELMINTIC DRUGS MARKET SIZE, BY HUMAN, 2018-2032 (USD MILLION)
  • TABLE 134. MIDDLE EAST ANTHELMINTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 135. MIDDLE EAST ANTHELMINTIC DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 136. MIDDLE EAST ANTHELMINTIC DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 137. AFRICA ANTHELMINTIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. AFRICA ANTHELMINTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 139. AFRICA ANTHELMINTIC DRUGS MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 140. AFRICA ANTHELMINTIC DRUGS MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 141. AFRICA ANTHELMINTIC DRUGS MARKET SIZE, BY FOOD PRODUCING ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 142. AFRICA ANTHELMINTIC DRUGS MARKET SIZE, BY HUMAN, 2018-2032 (USD MILLION)
  • TABLE 143. AFRICA ANTHELMINTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 144. AFRICA ANTHELMINTIC DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 145. AFRICA ANTHELMINTIC DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 146. ASIA-PACIFIC ANTHELMINTIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. ASIA-PACIFIC ANTHELMINTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 148. ASIA-PACIFIC ANTHELMINTIC DRUGS MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 149. ASIA-PACIFIC ANTHELMINTIC DRUGS MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 150. ASIA-PACIFIC ANTHELMINTIC DRUGS MARKET SIZE, BY FOOD PRODUCING ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 151. ASIA-PACIFIC ANTHELMINTIC DRUGS MARKET SIZE, BY HUMAN, 2018-2032 (USD MILLION)
  • TABLE 152. ASIA-PACIFIC ANTHELMINTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 153. ASIA-PACIFIC ANTHELMINTIC DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 154. ASIA-PACIFIC ANTHELMINTIC DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 155. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 156. ASEAN ANTHELMINTIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 157. ASEAN ANTHELMINTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 158. ASEAN ANTHELMINTIC DRUGS MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 159. ASEAN ANTHELMINTIC DRUGS MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 160. ASEAN ANTHELMINTIC DRUGS MARKET SIZE, BY FOOD PRODUCING ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 161. ASEAN ANTHELMINTIC DRUGS MARKET SIZE, BY HUMAN, 2018-2032 (USD MILLION)
  • TABLE 162. ASEAN ANTHELMINTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 163. ASEAN ANTHELMINTIC DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 164. ASEAN ANTHELMINTIC DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 165. GCC ANTHELMINTIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 166. GCC ANTHELMINTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 167. GCC ANTHELMINTIC DRUGS MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 168. GCC ANTHELMINTIC DRUGS MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 169. GCC ANTHELMINTIC DRUGS MARKET SIZE, BY FOOD PRODUCING ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 170. GCC ANTHELMINTIC DRUGS MARKET SIZE, BY HUMAN, 2018-2032 (USD MILLION)
  • TABLE 171. GCC ANTHELMINTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 172. GCC ANTHELMINTIC DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 173. GCC ANTHELMINTIC DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPEAN UNION ANTHELMINTIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPEAN UNION ANTHELMINTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPEAN UNION ANTHELMINTIC DRUGS MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPEAN UNION ANTHELMINTIC DRUGS MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPEAN UNION ANTHELMINTIC DRUGS MARKET SIZE, BY FOOD PRODUCING ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPEAN UNION ANTHELMINTIC DRUGS MARKET SIZE, BY HUMAN, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPEAN UNION ANTHELMINTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPEAN UNION ANTHELMINTIC DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPEAN UNION ANTHELMINTIC DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 183. BRICS ANTHELMINTIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 184. BRICS ANTHELMINTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 185. BRICS ANTHELMINTIC DRUGS MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 186. BRICS ANTHELMINTIC DRUGS MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 187. BRICS ANTHELMINTIC DRUGS MARKET SIZE, BY FOOD PRODUCING ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 188. BRICS ANTHELMINTIC DRUGS MARKET SIZE, BY HUMAN, 2018-2032 (USD MILLION)
  • TABLE 189. BRICS ANTHELMINTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 190. BRICS ANTHELMINTIC DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 191. BRICS ANTHELMINTIC DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 192. G7 ANTHELMINTIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 193. G7 ANTHELMINTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 194. G7 ANTHELMINTIC DRUGS MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 195. G7 ANTHELMINTIC DRUGS MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 196. G7 ANTHELMINTIC DRUGS MARKET SIZE, BY FOOD PRODUCING ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 197. G7 ANTHELMINTIC DRUGS MARKET SIZE, BY HUMAN, 2018-2032 (USD MILLION)
  • TABLE 198. G7 ANTHELMINTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 199. G7 ANTHELMINTIC DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 200. G7 ANTHELMINTIC DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 201. NATO ANTHELMINTIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 202. NATO ANTHELMINTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 203. NATO ANTHELMINTIC DRUGS MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 204. NATO ANTHELMINTIC DRUGS MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 205. NATO ANTHELMINTIC DRUGS MARKET SIZE, BY FOOD PRODUCING ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 206. NATO ANTHELMINTIC DRUGS MARKET SIZE, BY HUMAN, 2018-2032 (USD MILLION)
  • TABLE 207. NATO ANTHELMINTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 208. NATO ANTHELMINTIC DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 209. NATO ANTHELMINTIC DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 210. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 211. UNITED STATES ANTHELMINTIC DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 212. UNITED STATES ANTHELMINTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 213. UNITED STATES ANTHELMINTIC DRUGS MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 214. UNITED STATES ANTHELMINTIC DRUGS MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 215. UNITED STATES ANTHELMINTIC DRUGS MARKET SIZE, BY FOOD PRODUCING ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 216. UNITED STATES ANTHELMINTIC DRUGS MARKET SIZE, BY HUMAN, 2018-2032 (USD MILLION)
  • TABLE 217. UNITED STATES ANTHELMINTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 218. UNITED STATES ANTHELMINTIC DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 219. UNITED STATES ANTHELMINTIC DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 220. CHINA ANTHELMINTIC DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 221. CHINA ANTHELMINTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 222. CHINA ANTHELMINTIC DRUGS MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 223. CHINA ANTHELMINTIC DRUGS MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 224. CHINA ANTHELMINTIC DRUGS MARKET SIZE, BY FOOD PRODUCING ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 225. CHINA ANTHELMINTIC DRUGS MARKET SIZE, BY HUMAN, 2018-2032 (USD MILLION)
  • TABLE 226. CHINA ANTHELMINTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 227. CHINA ANTHELMINTIC DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 228. CHINA ANTHELMINTIC DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)